There is some evidence that haloperidol is an effective treatment for  acute mania .
From the limited data available , there was no difference in overall efficacy of treatment between haloperidol and olanzapine or risperidone .
Some evidence suggests that haloperidol could be less effective than aripiprazole .
BACKGROUND The main objectives in treating mania are to control dangerous behaviour , reduce suicide , produce appropriate acute sedation and shorten the episode of mood disturbance .
Among different drugs , haloperidol has for many years been used in treating psychotic patients , but it has a troublesome side effect profile .
OBJECTIVES To assess the effects of haloperidol for the treatment of mania in comparison with placebo or other active drugs , either as monotherapy or add-on treatment .
A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients.
BACKGROUND Behavioural and psychological symptoms ( BPSD ) are common during the course of dementia and present severe problems to patients and their caregivers . OBJECTIVES To assess the therapeutic efficacy and safety of haloperidol and risperidone in treating BPSD in Chinese dementia patients . METHODS A 12-week double-blind r and omised comparison of haloperidol and risperidone treatments was conducted in 58 patients with DSM-IV diagnosis of dementia of Alzheimer 's type or vascular dementia . They were r and omly assigned to receive flexible doses ( 0.5 to 2 mg/day ) of haloperidol or risperidone . Clinical response was evaluated using the Cohen-Mansfield Agitation Inventory ( CMAI ) , the Behavioral Pathology in Alzheimer 's Disease Rating Scale ( BEHAVE-AD ) , Simpson-Angus Scale , Functional Assessment Staging and Cantonese version of the Mini-Mental State Examination . RESULTS The mean doses at the last week were 0.90 mg/day of haloperidol and 0.85 mg/day of risperidone . Both haloperidol and risperidone significantly reduced the severity of BPSD ( scores on CMAI and BEHAVE-AD ) , with no significant between-group differences . Haloperidol-treated patients showed a worsening on Simpson-Angus scale while there was no significant change in this measure in risperidone-treated patients . CONCLUSIONS Low-dose haloperidol and risperidone were well tolerated and associated with reductions in the severity and frequency of behavioural symptoms in subjects with dementia .  Risperidone may have a more favourable risk-benefit profile in view of its lower propensity to induce extrapyramidal symptoms
There is some evidence that haloperidol is an effective treatment for  acute mania .
From the limited data available , there was no difference in overall efficacy of treatment between haloperidol and olanzapine or risperidone .
Some evidence suggests that haloperidol could be less effective than aripiprazole .
BACKGROUND The main objectives in treating mania are to control dangerous behaviour , reduce suicide , produce appropriate acute sedation and shorten the episode of mood disturbance .
Among different drugs , haloperidol has for many years been used in treating psychotic patients , but it has a troublesome side effect profile .
OBJECTIVES To assess the effects of haloperidol for the treatment of mania in comparison with placebo or other active drugs , either as monotherapy or add-on treatment .